Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients

Transplantation

Volumn 66, Issue 10, 1998, Pages 1330-1334

  Ljungman, Per ^a   Aschan, Johan ^a   Lewensohn Fuchs, Ilona ^a   Carlens, Stefan ^a   Larsson, Kajsa ^a   Lönnqvist, Berit ^a   Mattsson, Jonas ^a   Sparrelid, Elda ^a   Winiarski, Jacek ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

ADULT; ALLOGRAFT; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DNA DETERMINATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; RISK BENEFIT ANALYSIS; SEROCONVERSION; VIRUS INFECTION;

EID: 0032573604     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199811270-00012     Document Type: Article

References (32)

1. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation: European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749.
2. Goodrich J, Bowden R, Fisher L, Keller C, Schoch G, Meyers J. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173.
3. Winston D, Ho W, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179.
4. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063.
5. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815.
6. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601.
7. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative PCR for cytomegalovirus DNA as basis for preemptive therapy in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 583.
8. Ringdén O, Pihlstedt P, Markling L, et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate: a randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221.
9. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723.
10. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619.
11. Ringdén O, Groth CG, Aschan J, et al. Bone marrow transplantation for metabolic disorders at Huddinge Hospital. Transplant Proc 1990; 22: 198.
12. Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematologic malignancy. Bone Marrow Transplant 1986; 1: 41.
13. Thomas E, Storb R, Clift R, et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832 .
14. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Plotkin S, Michelson S, ed. Multidisciplinary approach to understanding cytomegalovirus disease. Vol. 1032. Amsterdam: Excerpta Medica International Congress Series, 1993: 233.
15. Ehrnst A, Barkholt L, Brattström C, et al. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993; 39: 118.
16. Ehrnst A, Barkholt L, Levensohn-Fuchs I, et al. CMV PCR monitoring in leukocytes of transplant patients. Clin Diagnost Virol 1995; 3: 139.
17. Ringdén, Pihlstedt P, Volin L, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1987; 2: 299.
18. Ruutu T, Ljungman P, Brinch L, et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 1997; 19: 233.
19. Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60: 1225.
20. Aschan J, Ringdén O, Ljungman P, Lönnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143.
21. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14: 831.
22. Bass E, Powe N, Goodman S, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12: 179.
23. Meyers J, Reed E, Shepp D, et al. Acyclovir for prevention of CMV infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70.
24. Meyers J, Flournoy N, Thomas E. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478.
25. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-versus-host disease. Blood 1986; 67: 1162.
26. Bowden R, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006.
27. Bowden R, Cays M, Schoch G, et al. Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood 1995; 86: 3598.
28. Ringdén O, Lönnqvist B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients [letter]. Bone Marrow Transplant 1989; 4: 713.
29. Ekelöf Andström E, Ringdén O, Remberger M, Svahn B-M, Tollemar J. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 1996; 39: 185.
30. Krause H, Hebart H, Jahn G, Muller C, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111.
31. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038.
32. Cope A, Sabin C, Burroughs A, Rolles K, Griffiths P, Emery V. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease. J Infect Dis 1997; 176: 1484.